Oak Thistle LLC Grows Stake in Zimmer Biomet Holdings, Inc. $ZBH

Oak Thistle LLC lifted its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 78.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 29,314 shares of the medical equipment provider’s stock after purchasing an additional 12,921 shares during the period. Oak Thistle LLC’s holdings in Zimmer Biomet were worth $2,636,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of ZBH. Key Financial Inc grew its stake in Zimmer Biomet by 164.6% during the 3rd quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 163 shares in the last quarter. Cullen Frost Bankers Inc. grew its stake in Zimmer Biomet by 66.7% during the 3rd quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 116 shares in the last quarter. Cary Street Partners Investment Advisory LLC grew its stake in Zimmer Biomet by 83.7% during the 2nd quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock valued at $30,000 after acquiring an additional 149 shares in the last quarter. Root Financial Partners LLC purchased a new stake in Zimmer Biomet during the 3rd quarter valued at about $31,000. Finally, Flagship Harbor Advisors LLC purchased a new stake in Zimmer Biomet during the 4th quarter valued at about $32,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on ZBH. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research note on Tuesday, February 10th. Robert W. Baird reaffirmed a “neutral” rating and set a $100.00 price objective (down from $117.00) on shares of Zimmer Biomet in a research note on Tuesday, December 16th. Weiss Ratings cut shares of Zimmer Biomet from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, March 23rd. TD Cowen raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Monday, January 26th. Finally, UBS Group reissued a “sell” rating and issued a $89.00 price target on shares of Zimmer Biomet in a research note on Wednesday, February 11th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, ten have issued a Hold rating and four have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Zimmer Biomet presently has a consensus rating of “Hold” and a consensus price target of $106.20.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 2,650 shares of the stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $94.66, for a total transaction of $250,849.00. Following the sale, the senior vice president directly owned 10,224 shares in the company, valued at $967,803.84. This represents a 20.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.70% of the stock is currently owned by company insiders.

Zimmer Biomet Stock Performance

Shares of ZBH stock opened at $91.38 on Wednesday. The firm’s 50 day moving average price is $92.51 and its 200-day moving average price is $93.49. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.10 and a current ratio of 1.98. Zimmer Biomet Holdings, Inc. has a one year low of $84.59 and a one year high of $108.29. The firm has a market cap of $17.69 billion, a P/E ratio of 25.81, a P/E/G ratio of 1.86 and a beta of 0.61.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $2.42 EPS for the quarter, topping the consensus estimate of $2.38 by $0.04. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The firm had revenue of $2.24 billion for the quarter, compared to analyst estimates of $2.22 billion. During the same period in the prior year, the business posted $2.31 EPS. The business’s revenue for the quarter was up 10.9% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. As a group, equities research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be issued a dividend of $0.24 per share. The ex-dividend date is Tuesday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. Zimmer Biomet’s dividend payout ratio is 27.12%.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.